Saudi Press

Saudi Arabia and the world
Saturday, Feb 22, 2025

Efficacy of Pfizer’s Covid-19 pill questioned

Efficacy of Pfizer’s Covid-19 pill questioned

An Israeli study has indicated the medication is of little measurable benefit to patients in the 40-65 age bracket
A Covid-19 pill lauded by the World Health Organization (WHO) may be of little or no benefit to patients aged between 40 and 65, a new study by Israeli researchers has suggested. The medication, made by Pfizer and sold under the trade name Paxlovid, has proven effective in those aged over 65, however.

Published in the New England Journal of Medicine on Wednesday, the study involved 109,000 patients who had received Paxlovid. After analyzing different age brackets, the scientists concluded that the treatment did little to improve the conditions of patients aged 40 to 65. At the same time, the medication reduced the number of hospitalizations among seniors by approximately 75%, if given shortly after contracting Covid-19.

The analysis, however, is based on data obtained from the Israeli health system as opposed to observing patients in a randomized study with a control group – something which represents a departure from practices held as the standard for such research, AP pointed out.

No official comment from Pfizer has been forthcoming as of yet.

The US Food and Drug Administration authorized Paxlovid late last year for adults and children over 12 who suffer from chronic conditions like obesity, diabetes and heart disease. According to federal records cited by AP, over 3.9 million prescriptions for the medication have been issued since the drug was given the green light.

The Biden administration has been placing particular emphasis on Paxlovid in the hope of reducing the number of hospitalizations. US authorities are said to have shelled out some $10 billion to procure the drug, which is being made available to the public at thousands of pharmacies through the government’s test-and-treat initiative.

In an emailed statement on Wednesday, White House spokesperson Kevin Munoz cited several other studies which indicate that Paxlovid helps reduce hospitalizations among people 50 and older. That research, however, has yet to be published in peer-reviewed journals, AP noted.

The official was quoted as saying that the “growing body of evidence is showing that individuals between the ages of 50 and 64 can also benefit from Paxlovid.”
Newsletter

Related Articles

Saudi Press
0:00
0:00
Close
Saudi Arabia and the United States Strengthen Ties Amid Global Developments
Saudi Arabia Hosts Global Conference to Promote Islamic Unity
The Impact of Artificial Intelligence on Education and Child Development
Saudi Arabia Announces Competition for Best Founding Day Outfits
Saudi-EU Food Security Officials Hold Talks to Strengthen Collaboration
Putin Expresses Gratitude to Saudi Crown Prince for Hosting US-Russia Talks
UK and Saudi Arabia Enhance Collaboration in Innovation and Technology
Denmark's Embassy in Riyadh Showcases Danish Cuisine with Saudi Influence
Saudi Artist Salman Al-Amir Unveils 'Tafawut' Exhibition in Riyadh
Saudi Arabia Offers Condolences to Kuwait Following Military Exercise Fatalities
Saudi Ministry of Islamic Affairs Completes Ramadan Preparations in Madinah
Etidal Secretary-General Hosts UN Counter-Terrorism Director in Riyadh
ADNOC Drilling Targets Over $1 Billion in Investments for 2025 Amid Gulf Expansion Plans
Derayah Financial Achieves Remarkable Growth in Saudi Brokerage and Asset Management
Saudi Arabia Shortlists 30 Firms for Mining Licenses in Eastern Province and Tabuk
Saudi Foreign Minister Engages Counterparts at G20 Meeting in Johannesburg
Oil Prices Decline Amid Rising US Inventories
Saudi Arabia's NDMC Plans Green Bond Issuance by 2025
Moody’s Affirms Egypt’s Caa1 Rating Amid Positive Economic Outlook
Oman and Saudi Arabia Strengthen Economic Ties with New Agreements
Saudi Arabia Investments Propel Expansion of Qurayyah Power Plant
Saudi Capital Market Authority Advances SPACs and Direct Listings
Global Energy Leaders Gather in Riyadh for Symposium on Energy Outlooks
Al-Ahsa Region Sees 500% Growth in Tourism as Saudi Arabia Prioritizes Development
Saudi Arabia Advances Entrepreneurial Ecosystem in Al-Ahsa with New Agreement
King Salman Approves Official Saudi Riyal Symbol
Saudi Credit Card Lending Reaches $8.4 Billion Amid Digital Payment Expansion
King Salman Approves Official Symbol for Saudi Riyal
Putin Thanks Saudi Crown Prince for Facilitating U.S.-Russia Discussions
Saudi Foreign Minister Attends G20 Meeting in Johannesburg
Saudi Arabia Prepares for Nationwide Founding Day Celebrations
Inauguration of Hira Park and Walkway Enhances Jeddah's Urban Landscape
Crown Prince Hosts Leaders for Informal Meeting in Riyadh Amid Gaza Rebuilding Plans
Saudi Official Highlights Achievements and Media's Role in National Transformation
Three Expatriate Women Arrested for Prostitution in Riyadh
Saudi Arabia's Diplomatic Evolution Highlighted at Saudi Media Forum
Healthy Eating and Preparation Essential for Ramadan Fasting
Saudi Arabia and Japan Forge Sustainable Textile Partnership
Advanced Limb Surgery Restores Mobility in Pediatric Cancer Patient
Jeddah Event Explores AI's Role in Boosting Saudi Arabia's SME Sector
UN Representative Highlights AI's Role in Perpetuating Gender Stereotypes
Saudi and Jordanian Leaders Discuss Enhanced Security Cooperation in Amman
Saudi British Society Honors Cultural Bridge-Builders at London Gala
Saudi Media Forum 2025 Explores AI's Role in Modern Journalism
Saudi Arabia's Saqer Al-Moqbel Appointed as WTO General Council President for 2025–2026
Saudi Deputy Ministers Engage in Diplomatic Discussions with U.S. and Dutch Officials in Riyadh
Saudi Arabia to Launch Iftar Program in 61 Countries During Ramadan
Saudi Visitors Expected to Spend £942 Million in UK During 2025
Saudi Arabia Gifts Kaaba's Kiswah to Uzbekistan's Center of Islamic Civilization
Digital Cooperation Organization Concludes Fourth General Assembly with Multiple Agreements
×